Heparin length in the coating of extremely small iron oxide nanoparticles regulates


Journal

Nanoscale
ISSN: 2040-3372
Titre abrégé: Nanoscale
Pays: England
ID NLM: 101525249

Informations de publication

Date de publication:
21 Jan 2021
Historique:
pubmed: 23 12 2020
medline: 15 5 2021
entrez: 22 12 2020
Statut: ppublish

Résumé

The positive contrast of extremely small iron oxide nanoparticles (ESIONP) in magnetic resonance imaging (MRI) rejuvenates this class of metal nanoparticles (NP).Yet, the current synthesis often lacks the possibility of adjusting the core size (while it is a key element for ESIONP-based MRI contrast behaviour), and also involved multiple complex steps before obtaining a ready-to-use probe for medical applications. In this study, we faced these challenges by applying heparin oligosaccharides (HO) of different lengths as coatings for the preparation of HEP-ESIONP with a one-pot microwave method. We demonstrated that the HO length could control the core size during the synthesis to achieve optimal positive MRI contrast, and that HEP-ESIONP were endowed directly with anticoagulant properties and/or a specific antitumor activity, according to the HO used. Relevantly, positron emission tomography (PET)-based in vivo biodistribution study conducted with 68Ga core-doped HEP-ESIONP analogues revealed significant changes in the probe behaviours, the shortening of HO promoting a shift from hepatic to renal clearance. The different conformations of HO coatings and a thorough in vitro characterisation of the probes' protein coronas provided insight into this crucial impact of HO length on opsonization-mediated immune response and elimination. Overall, we were able to identify a precise HO length to get an ESIONP probe showing prolonged vascular lifetime and moderate accumulation in a tumor xenograft, balanced with a low uptake by non-specific organs and favourable urinary clearance. This probe met all prerequisites for advanced theranostic medical applications with a dual MRI/PET hot spot capability and potential antitumor activity.

Identifiants

pubmed: 33351869
doi: 10.1039/d0nr06378a
doi:

Substances chimiques

Ferric Compounds 0
Heparin 9005-49-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

842-861

Auteurs

Hugo Groult (H)

BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France. hugo.groult@univ-lr.fr thierry.maugard@univ-lr.fr.

Susana Carregal-Romero (S)

CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. jruizcabello@cicbiomagune.es and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

David Castejón (D)

Unidad de RMN - CAI Bioimagen Complutense, Universidad Complutense de Madrid, Spain.

Mikel Azkargorta (M)

Proteomics Platform CIC bioGUNE, Bizkaia Science and Technology, Derio, Spain.

Ana-Beatriz Miguel-Coello (AB)

CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. jruizcabello@cicbiomagune.es.

Krishna Reddy Pulagam (KR)

CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. jruizcabello@cicbiomagune.es.

Vanessa Gómez-Vallejo (V)

CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. jruizcabello@cicbiomagune.es.

Rémi Cousin (R)

BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France. hugo.groult@univ-lr.fr thierry.maugard@univ-lr.fr.

María Muñoz-Caffarel (M)

Molecular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.

Charles H Lawrie (CH)

Molecular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.

Jordi Llop (J)

CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. jruizcabello@cicbiomagune.es and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Jean-Marie Piot (JM)

BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France. hugo.groult@univ-lr.fr thierry.maugard@univ-lr.fr.

Felix Elortza (F)

Proteomics Platform CIC bioGUNE, Bizkaia Science and Technology, Derio, Spain.

Thierry Maugard (T)

BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France. hugo.groult@univ-lr.fr thierry.maugard@univ-lr.fr.

Jesús Ruiz-Cabello (J)

CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. jruizcabello@cicbiomagune.es and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain and Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Madrid, Spain.

Ingrid Fruitier-Arnaudin (I)

BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France. hugo.groult@univ-lr.fr thierry.maugard@univ-lr.fr.

Articles similaires

Humans Ketamine Propofol Pulmonary Atelectasis Female
Humans Magnetic Resonance Imaging Phantoms, Imaging Infant, Newborn Signal-To-Noise Ratio
Animals Humans Nickel Mice Immunotherapy
1.00
Humans Magnetic Resonance Imaging Brain Infant, Newborn Infant, Premature

Classifications MeSH